NewLink Genetics to Present at 2014 Leerink Global HealthcareConference
AMES, IA, Feb 11, 2014 (Menafn - Marketwired via COMTEX) --NewLink Genetics Corporation NLNK, a biopharmaceuticalcompany focused on discovering, developing and commercializing novelimmunotherapeutics to improve treatment options for patients withcancer, announced today that Nicholas Vahanian, M.D., NewLink'sPresident and Chief Medical Officer, is scheduled to present at the2014 Leerink Global Healthcare Conference in New York on Thursday,February 13, 2014 at 3:05 p.m. ET.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering,developing and commercializing novel immunotherapeutic products toimprove treatment options for patients with cancer. NewLink'sportfolio includes biologic and small molecule immunotherapy productcandidates intended to treat a wide range of oncology indications.NewLink's product candidates are designed to harness multiplecomponents of the immune system to combat cancer without significantincremental toxicity, either as a monotherapy or in combination withother treatment regimens. For more information please visithttp://www.linkp.com.
Chief Financial Officer
SOURCE: NewLink Genetics Corporation
(C) 2014 Marketwire L.P. All rights reserved.